90
Active Trials
38
Phase 1
25
Phase 2
39
Phase 3
12
Therapeutic Areas
Portfolio Concentration: 62% of active trials in Oncology
Oncology
56 active / 62 total
Solid Tumor (Advanced)
17 active
17 total since 2015
NSCLC
6 active
3 Ph3
7 total since 2015
Multiple Myeloma
5 active
2 Ph3
5 total since 2015
Colorectal Cancer
4 active
2 Ph3
4 total since 2015
Pancreatic Cancer
3 active
1 Ph3
4 total since 2015
Gastric Cancer
3 active
3 total since 2015
Prostate Cancer
3 active
1 Ph3
3 total since 2015
Breast Cancer
2 active
1 Ph3
4 total since 2015
Lung Cancer (General)
2 active
2 Ph3
3 total since 2015
Esophageal Cancer
2 active
1 Ph3
2 total since 2015
Endometrial Cancer
1 active
1 total since 2015
Ovarian Cancer
1 active
1 total since 2015
Head and Neck Cancer
1 active
1 total since 2015
HER2- Breast Cancer
1 active
1 total since 2015
Hematologic Malignancies
1 active
1 total since 2015
Triple Negative Breast Cancer
1 active
1 Ph3
1 total since 2015
Cholangiocarcinoma
1 active
1 total since 2015
SCLC
1 active
1 Ph3
1 total since 2015
Hepatocellular Carcinoma
1 active
1 Ph3
1 total since 2015
Cervical Cancer
0 active
1 total since 2015
Immunology
12 active / 15 total
Cardiovascular
7 active / 8 total
Metabolic
6 active / 6 total
CNS
5 active / 5 total
Respiratory
3 active / 3 total
Rare Disease
2 active / 5 total
Urology
2 active / 2 total
Musculoskeletal
2 active / 2 total
Ophthalmology
1 active / 4 total
Women's Health
1 active / 2 total
Gastrointestinal
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)